Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study

British Journal of Rheumatology

Volumn 35, Issue 8, 1996, Pages 738-745

  Jones, M ^a   Symmons, D ^a,c   Finn, J ^a   Wolfe, F ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^c ARC Epidemiology Research Unit   (United Kingdom)

Author keywords

Cancer; Immunosuppressives; Matched cohort; Mortality; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RAZOXANE; STEROID;

ARTICLE; CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

EID: 0029759669     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.8.738     Document Type: Article

References (19)

1. Diaz J. The treatment of dysreaction diseases with nitrogen mustards. Ann Rheum Dis 1951;10:144-51.
2. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963;117:385-95.
3. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106-12.
4. Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6.
5. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive therapy. Am J Med 1985;78(1A):44-9.
6. Renier J-C, Bregeon Ch, Bonnette Ch et al. Le devenir des sujets atteints de polyarthrite rhumatoide et traités par les immunodépresseurs entre 1965 et 1973 inclus. Rev Rhum 1978;45:453-61.
7. Kamel OW, van de Rijn M, Weiss LM et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
8. Kay A. EULAR register of patients on immunosuppressive drugs. Ann Rheum Dis 1982;41(suppl. 1):30-2.
9. Matteson EL, Hickey AR, Maguire L et al. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991;18: 809-14.
10. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31: 691-6.
11. Prior P, Symmons DPM, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;54:128-31.
12. Gridley G, Mclaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
13. Tennis P, Andrews E, Bombardier C et al. Record linkage to conduct an epidemiologic study on the association between rheumatoid arthritis and lymphoma in the province of Saskatchewan Canada. J Clin Epidemiol 1993;46:685-95.
14. Selvin S. Statistical analysis of epidemiological data. Oxford: Oxford University Press, 1991.
15. OPCS mortality statistics 1980-1990. London: HMSO Publications.
16. United States Department of Health and Human Services: vital statistics of the USA. 1980-1990. National Centre for Health Statistics, 1980-1990.
17. Farber SJ, Shern RP, Kirsner AB, Finkel RI. Incidence of malignant diseases in patients receiving cytotoxic therapy for rheumatoid arthritis. Arthritis Rheum 1979;22:608.
18. Balthaus JAM, Boersma JW, Hartman AP, Vanden-broucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophos-phamide: a controlled retrospective follow-up. Ann Rheum Dis 1983;42:368-73.
19. Silman AJ, Petrie J, Hazleman B, Evans SJW. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow-up study. Ann Rheum Dis 1988;47:988-92.